Product
Oritavancin Diphosphate and Warfarin
1 clinical trial
1 indication
Indication
HealthyClinical trial
An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.Status: Completed, Estimated PCD: 2015-09-01